

1. Record Nr.	UNINA9910502985803321
Autore	Nemade Sanjana Vijay
Titolo	Granulomatous diseases in otorhinolaryngology, head and neck / / Sanjana Vijay Nemade, Kiran Jaywant Shinde
Pubbl/distr/stampa	Singapore : , : Springer, , [2021] ©2021
ISBN	981-16-4047-5
Descrizione fisica	1 online resource (329 pages)
Disciplina	616.0473
Soggetti	Granuloma Otolaryngology - Diagnosis Tumors Otorrinolaringologia Llibres electrònics
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di contenuto	Intro -- Preface -- Acknowledgement -- Introduction -- Clinical Features of Granulomatous Diseases -- Diagnosis of Granulomatous Diseases -- Treatment of Granulomatous Diseases -- Contents -- About the Authors -- Part I: Autoimmune Granulomatous Diseases -- 1: Granulomatosis with Polyangiitis-GPA (Wegener's Granulomatosis) -- 1.1 Background -- 1.2 Epidemiology -- 1.3 Etiopathogenesis -- 1.4 Clinical Features -- 1.4.1 Sinonasal Features -- 1.4.2 Oropharyngeal Features -- 1.4.3 Laryngotracheal Involvement -- 1.4.4 Otological Features -- 1.4.4.1 Hearing Loss -- 1.4.4.2 Vertigo or Disequilibrium -- 1.4.4.3 Facial Paralysis -- 1.4.5 Salivary Gland Involvement -- 1.4.6 Other System Involvement -- 1.5 Diagnosis -- 1.5.1 Classification Criteria for GPA -- 1.5.1.1 Histopathology -- 1.5.1.2 Serology -- 1.5.1.3 Endoscopy -- 1.5.1.4 Imaging: -- 1.5.1.5 Pulmonary Function Tests: -- 1.6 Treatment -- 1.6.1 Maintainance of Remission -- 1.7 Essential Features -- References -- 2: Churg- Strauss Syndrome -- 2.1 Background -- 2.2 Epidemiology -- 2.3 Etiopathogenesis -- 2.4 Clinical Features -- 2.5 Diagnosis -- 2.5.1 The Six Criteria -- 2.5.2 Endoscopy -- 2.5.3 The Birmingham

Vasculitis Activity Score (BVAS) -- 2.5.4 Blood Cells and Biomarkers -- 2.5.5 Imaging -- 2.5.6 Histopathology -- 2.5.7 Other Tests -- 2.6 Treatment -- 2.6.1 Oral Corticosteroids and Immunosuppressants -- 2.6.2 Supportive Therapy -- 2.7 Essential Features -- References -- 3: Behcet's Disease -- 3.1 Overview -- 3.2 Epidemiology -- 3.3 Etiopathogenesis -- 3.4 Clinical Features -- 3.4.1 Other System Involvement -- 3.5 Diagnosis -- 3.5.1 Histopathology -- 3.5.2 Other Tests -- 3.6 Treatment -- 3.6.1 Pharmacotherapy -- 3.6.2 Surgery -- 3.7 Essential Features -- References -- Part II: Infective Granulomatous Diseases -- 4: Tuberculosis -- 4.1 Background. 4.2 Epidemiology -- 4.3 Etiopathogenesis -- 4.3.1 There are Two Major Patterns of Disease with TB -- 4.4 Clinical Features -- 4.4.1 Laryngeal TB -- 4.4.2 TB of Cervical Lymph Nodes -- 4.4.3 Aural TB -- 4.4.4 Nasal TB -- 4.4.5 TB in the Oral Cavity and Oropharynx -- 4.5 Diagnosis -- 4.5.1 Microscopy and Culture -- 4.5.2 Histopathology -- 4.5.3 Imaging -- 4.5.4 The Mantoux Tuberculin Skin Test -- 4.5.5 Serology -- 4.5.6 Molecular Assay -- 4.5.6.1 Nucleic Acid Amplification Tests -- 4.5.7 Latent TB -- 4.5.8 New Cases of Active TB -- 4.5.9 Previously Treated Cases -- 4.5.9.1 The Standard Re-treatment Regimen Consists of -- 4.5.10 Treatment of Drug-Resistant Tuberculosis -- 4.5.10.1 Medication Administration -- 4.5.10.2 Duration of Treatment -- 4.5.10.3 Surgical Management -- 4.5.10.4 Vaccination -- 4.6 Essential Features -- References -- 5: Syphilis -- 5.1 Background -- 5.2 Epidemiology -- 5.3 Etiopathogenesis -- 5.3.1 Primary Syphilis -- 5.3.2 Secondary Syphilis -- 5.3.3 Tertiary Syphilis (Gummatous Syphilis) -- 5.3.4 Congenital Syphilis -- 5.4 Clinical Features -- 5.4.1 Ear Manifestations -- 5.4.2 The Oral Cavity and Oropharyngeal Manifestations -- 5.4.3 The Larynx and Hypopharyngeal Manifestations -- 5.4.4 The Nose and Nasopharyngeal Manifestations -- 5.5 Diagnosis -- 5.5.1 Clinical Diagnosis is Aided by the Following Diagnostic Tests [18] -- 5.5.2 Darkfield Examination -- 5.5.3 Serologic Tests -- 5.5.4 Histopathology -- 5.5.5 Imaging -- 5.6 Treatment -- 5.6.1 Primary, Secondary, and Early Tertiary Disease -- 5.6.1.1 First-Line Treatment -- 5.6.2 Late Tertiary Disease -- 5.6.2.1 First-Line Treatment -- 5.6.2.2 Alternate Treatment -- 5.6.3 Surgical Management -- 5.7 Essential Features -- References -- 6: Leprosy -- 6.1 Background -- 6.2 Epidemiology -- 6.3 Etiopathogenesis. 6.4 Clinical Features -- 6.5 ENT Manifestations -- 6.6 Diagnosis -- 6.6.1 Histopathology -- 6.6.2 Serology -- 6.6.3 Molecular Assay -- 6.6.4 Other Tests -- 6.6.5 Interpretation -- 6.6.6 Imaging -- 6.7 Treatment -- 6.7.1 WHO Recommendations for Treatment of Leprosy [14] -- 6.7.2 United States Recommendations for Treatment of Leprosy [14] -- 6.7.2.1 Surgical Management -- 6.8 Essential features -- References -- 7: Actinomyces -- 7.1 Background -- 7.2 Epidemiology -- 7.3 Etiopathogenesis -- 7.4 Clinical Features -- 7.4.1 Other Features -- 7.5 Diagnosis -- 7.5.1 Cytology -- 7.5.2 Culture -- 7.5.3 Histopathology -- 7.5.4 Imaging -- 7.5.5 Serology -- 7.5.6 Molecular Assay -- 7.6 Treatment -- 7.7 Essential Features -- References -- 8: Rhinoscleroma -- 8.1 Background -- 8.2 Epidemiology -- 8.3 Etiopathogenesis -- 8.4 Clinical Features -- 8.5 Complications -- 8.6 Diagnosis -- 8.6.1 Endoscopy -- 8.6.2 Microscopy and Culture -- 8.6.3 Histopathology -- 8.6.3.1 The Histologic Findings Correspond to the Three Clinical Stages [7, 8] -- 8.6.4 Imaging -- 8.7 Treatment -- 8.7.1 Surgical Management -- 8.8 Essential Features -- References -- 9: Cat Scratch Disease -- 9.1 Background -- 9.2 Epidemiology -- 9.3 Etiopathogenesis -- 9.4 Clinical Features -- 9.5 Diagnosis -- 9.5.1 Imaging -- 9.5.2 Fine

Needle Aspiration Cytology -- 9.5.3 Lymph Node Biopsy -- 9.5.4 Serology -- 9.5.5 Molecular Assay -- 9.6 Treatment -- 9.7 Essential Features -- References -- 10: Lyme Disease -- 10.1 Background -- 10.2 Epidemiology -- 10.3 Etiopathogenesis -- 10.4 Clinical Features -- 10.4.1 Stages of Disease -- 10.4.1.1 Early Localized Infection -- 10.4.1.2 Early Disseminated Infection -- Nervous System Involvement (Neuroborreliosis) -- Cardiovascular Involvement -- 10.4.1.3 Late Disseminated Infection -- 10.5 Diagnosis. 10.5.1 Microscopy and Culture -- 10.5.2 Histopathology -- 10.5.3 Immunohistochemistry -- 10.5.4 Serology -- 10.5.5 Molecular Assay -- 10.5.6 Imaging -- 10.5.7 Other Tests -- 10.6 Treatment -- 10.7 Essential Features -- References -- 11: Tularemia -- 11.1 Background -- 11.2 Epidemiology -- 11.3 Etiopathogenesis -- 11.4 Clinical Features -- 11.5 Diagnosis -- 11.5.1 Culture -- 11.5.2 Serology -- 11.5.3 Molecular Assay -- 11.5.4 Histopathology -- 11.5.5 Imaging -- 11.6 Treatment -- 11.6.1 First-Line Therapy -- 11.6.2 Second-Line Therapy -- 11.7 Essential Features -- References -- 12: Aspergillosis -- 12.1 Background -- 12.2 Epidemiology -- 12.3 Etiopathogenesis -- 12.4 Risk Factors -- 12.5 Clinical Features -- 12.5.1 Saprophytic Aspergillosis -- 12.5.1.1 Aspergilloma (Fungal Ball) -- 12.5.1.2 Chronic Pulmonary Aspergillosis (CPA) -- 12.5.2 Allergic Aspergillosis -- 12.5.3 Invasive Aspergillosis -- 12.6 Diagnosis -- 12.6.1 Microscopy and Culture -- 12.6.2 Histopathology -- 12.6.3 Immunohistochemistry for Fungal Identification -- 12.6.4 Imaging -- 12.6.5 Serology -- 12.6.6 Molecular Assay -- 12.6.7 Other Tests -- 12.7 Treatment -- 12.7.1 Invasive Aspergillosis (IA) -- 12.7.2 Noninvasive Aspergillosis -- 12.7.3 Glucocorticoids -- 12.7.4 Antifungal Drugs -- 12.7.5 Anti-IgE Therapy -- 12.7.6 Anti-Th2 Therapies -- 12.7.7 Surgical Management -- 12.8 Essential Features -- References -- 13: Mucormycosis -- 13.1 Background -- 13.2 Epidemiology -- 13.3 Etiopathogenesis -- 13.4 Classification -- 13.4.1 Predisposing Factors -- 13.5 Clinical Features -- 13.6 Diagnosis -- 13.6.1 Microscopy and Culture -- 13.6.2 Culture -- 13.6.3 Histopathology -- 13.6.4 Serology -- 13.6.5 Molecular Assay -- 13.6.6 Imaging -- 13.7 Treatment -- 13.7.1 First-Line Monotherapy. 13.7.2 Dose of AmB (amphotericin B deoxycholate) -- 13.7.3 Salvage Therapy -- 13.7.4 Surgical Management -- 13.7.5 Post Covid-19 Mucormycosis (From Frying Pan to Fire) -- 13.8 Essential Features -- References -- 14: Rhinosporidiosis -- 14.1 Background -- 14.2 Epidemiology -- 14.3 Etiopathogenesis -- 14.4 Clinical Features -- 14.4.1 Symptoms -- 14.4.2 Signs of Nasal Rhinosporidiosis Mass -- 14.5 Diagnosis -- 14.5.1 Cytology and Histopathology -- 14.5.2 Serology -- 14.5.3 Imaging -- 14.6 Treatment -- 14.7 Essential Features -- References -- 15: Candidiasis -- 15.1 Background -- 15.2 Epidemiology -- 15.2.1 Global Emergence of Candida Auris -- 15.2.2 3 Major Concerns About It Are -- 15.3 Etiopathogenesis -- 15.3.1 Virulence Properties of Candida Species -- 15.4 Clinical Features -- 15.4.1 Primary Candidiasis -- 15.4.2 Secondary Candidiasis -- 15.5 Candida-Associated Lesions -- 15.5.1 Denture stomatitis -- 15.6 Diagnosis -- 15.6.1 Microscopy and Culture -- 15.6.2 Histopathology -- 15.6.3 Candida Species Identification -- 15.6.4 Endoscopy -- 15.6.5 Imaging -- 15.6.6 Serology -- 15.6.7 Molecular Assay -- 15.6.8 Blood Tests -- 15.7 Treatment -- 15.8 Essential Features -- References -- 16: Histoplasmosis -- 16.1 Background -- 16.2 Epidemiology -- 16.3 Etiopathogenesis -- 16.4 Clinical Features -- 16.5 Diagnosis -- 16.5.1 Microscopy -- 16.5.2 Culture -- 16.5.3 Histopathology -- 16.5.4 Serology -- 16.5.5 Imaging -- 16.6

Treatment -- 16.7 Essential Features -- References -- 17:
Cryptococcosis -- 17.1 Background -- 17.2 Epidemiology -- 17.3
Etiopathogenesis -- 17.4 Clinical Features -- 17.4.1 CNS
Manifestations -- 17.4.2 Pulmonary Cryptococcosis -- 17.4.3
Cutaneous and Mucocutaneous Cryptococcosis -- 17.4.4 Other
Manifestations -- 17.5 Diagnosis -- 17.5.1 Microscopy and Culture
-- 17.5.2 Histopathology.
17.5.3 Differentiation Between *C. neoformans* and *C. gattii*.
